Scope of the Study
The rheumatology devoted to adequate diagnosis and therapy of rheumatic diseases including clinical problems in joints, soft tissues, heritable connective tissue disorders, vasculitis and autoimmune diseases. Rheumatology therapeutic is a treatment of rheumatic diseases. The rheumatology diseases generally affect the supporting and connecting structures and bones like muscles, ligaments, joints etc. Rheumatology Therapeutics market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024.
The market study is being classified by Type (Disease Modifying Anti-rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids and Uric Acid Drugs) and major geographies with country level break-up.
AbbVie, Inc. (United States), Bristol-Myers Squibb Company (United States), Pfizer (United States), Merck & Co., Inc. (United States), Amgen, Inc. (United States), Novartis AG (Switzerland), Janssen Biotech, Inc. (United States), Sanofi (France), Genentech, Inc. (United States) and Takeda Pharmaceutical (Japan) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Rheumatology Therapeutics market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Rheumatology Therapeutics market by Type, Application and Region.
On the basis of geography, the market of Rheumatology Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Chanel, the sub-segment i.e. Hospital Pharmacy will boost the Rheumatology Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Parenteral Route will boost the Rheumatology Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease, the sub-segment i.e. Rheumatoid Arthritis will boost the Rheumatology Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Population with Rheumatology Arthritis Worldwide
- Increase in the Number of New Drugs Approved
- Demand for Drugs with Improved Quality
- Patent Expiration of the Some Drugs
- Lack of Awareness about Treatment among Developing Countries
- Growing Geriatric Population Worldwide
- Rising Demand for Biosimilar Products
- High Research and Development Cost
On 19th February 2019, AbbVie, Inc., a research-based global biopharmaceutical company, announced that United States Food and Drug Administration (FDA) accepted for priority review its New Drug Application (NDA) for upadacitinib for the treatment of adult patients with moderate to severe rheumatoid arthritis.
Key Target AudienceRheumatology Therapeutic Drugs Manufacturers, Raw Material Suppliers/ Buyers, Distributors, Research Organization and Associations, Government Body & Associations and End-user
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase